Top

Published in:

01-02-2014 | Review

Quantitative assessment of the association between XPG Asp1104His polymorphism and bladder cancer risk

Authors: Chuan Liu, Qinghua Yin, Jianbing Hu, Jie Weng, Yajie Wang

Published in: Tumor Biology | Issue 2/2014

Abstract

Published data regarding the association between XPG Asp1104His polymorphism and bladder cancer risk remained controversial. This meta-analysis of literatures was performed to draw a more precise estimation of the relationship. We systematically searched PubMed, Embase, and Web of Science with a time limit of June 22, 2013. Summary odds ratios (ORs) with 95 % CIs were used to assess the strength of the association between XPG Asp1104His polymorphism and bladder cancer risk using random effects model. A total of eight case–control studies including 2,613 cases and 2,934 controls were included for analysis. Overall, no significant association was found between XPG Asp1104His polymorphism and bladder cancer susceptibility for CC vs. GG (OR = 1.12, 95 % CI = 0.74–1.69), GC vs. GG (OR = 1.12, 95 % CI = 0.86–1.46), the dominant model CC + GC vs. GG (OR = 1.08, 95 % CI = 0.85–1.38), and the recessive model CC vs. GC + GG (OR = 0.92, 95 % CI = 0.66–1.29). In the subgroup analysis, no significant associations were found in either Asian or non-Asian population. This meta-analysis suggested that XPG Asp1104His polymorphism was not associated with bladder cancer risk.

Jemal A, Bray F, Melissa M, Ferlay J, Ward E. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.PubMedCrossRef

Bertuccio P, Chatenoud L, Levi F, Praud D, Ferlay J, Negri E, et al. Recent patterns in gastric cancer: a global overview. Int J Cancer. 2009;125:666–73.PubMedCrossRef

Hayes JD, Flanagan JU, Jowsey IR. Glutathione transferases. Annu Rev Pharmacol Toxicol. 2005;45:51–88.PubMedCrossRef

Naccarati A, Pardini B, Hemminki K, Vodicka P. Sporadic colorectal cancer and individual susceptibility: a review of the association studies investigating the role of DNA repair genetic polymorphisms. Mutat Res. 2007;635:118–45.PubMedCrossRef

Tse D, Zhai R, Zhou W, Heist RS, Asomaning K, Su L, et al. Polymorphisms of the NER pathway genes, ERCC1 and XPD are associated with esophageal adenocarcinoma risk. Cancer Causes Control. 2008;19:1077–83.PubMedCentralPubMedCrossRef

Araujo SJ, Nigg EA, Wood RD. Strong functional interactions of TFIIH with XPC and XPG in human DNA nucleotide excision repair, without a preassembled repairosome. Mol Cell Biol. 2001;21:2281–91.PubMedCentralPubMedCrossRef

Scherly D, Nouspikel T, Corlet J, Ucla C, Bairoch A, Clarkson SG. Complementation of the DNA repair defect in xeroderma pigmentosum group G cells by a human cDNA related to yeast RAD2. Nature. 1993;363:182–5.PubMedCrossRef

Emmert S, Schneider TD, Khan SG, Kraemer KH. The human XPG gene: gene architecture, alternative splicing and single nucleotide polymorphisms. Nucleic Acids Res. 2001;29:1443–52.PubMedCentralPubMedCrossRef

Stephens JC, Schneider JA, Tanguay DA, Choi J, Acharya T, Stanley SE, et al. Haplotype variation and linkage disequilibrium in 313 human genes. Science. 2001;293:489–93.PubMedCrossRef

10.

Juson R, Stenphen JC, Windemuth A. The predictive power of haplotypes in clinical response. Pharmacogenomics. 2000;1:15–6.CrossRef

11.

Fallin D, Cohen A, Essioux L, Chumakov I, Blumenfeld M, Cohen D, et al. Genetic analysis of case/control data using estimated haplotype frequencies: application to APOE locus variation and Alzheimer’s disease. Genome Res. 2001;11:143–51.PubMedCrossRef

12.

Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603–5.PubMedCrossRef

13.

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.PubMedCrossRef

14.

Ades AE, Lu G, Higgins JP. The interpretation of random-effects meta-analysis in decision models. Med Decis Making. 2005;25:646–54.PubMedCrossRef

15.

Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMed

16.

Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963–74.PubMedCrossRef

17.

Cochran WG. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.CrossRef

18.

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.PubMedCrossRef

19.

Ioannidis JP, Boffetta P, Little J, O’Brien TR, Uitterlinden AG, Vineis P, et al. Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol. 2008;37:120–32.PubMedCrossRef

20.

Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–101.PubMedCrossRef

21.

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.PubMedCrossRef

22.

Wen H, Feng CC, Fang ZJ, Xia GW, Jiang HW, Xu G, et al. Study on bladder cancer susceptibility and genetic polymorphisms of XPC, XPG, and CYP in smokers and non-smokers. Actas Urol Esp. 2012;37(5):259–65.PubMed

23.

Rouissi K, Ouerhani S, Hamrita B, Bougatef K, Marrakchi R, Cherif M, et al. Smoking and polymorphisms in xenobiotic metabolism and DNA repair genes are additive risk factors affecting bladder cancer in Northern Tunisia. Pathol Oncol Res. 2011;17:879–86.PubMedCrossRef

24.

Rouissi K, Bahria IB, Bougatef K, Marrakchi R, Stambouli N, Hamdi K, et al. The effect of tobacco, XPC, ERCC2 and ERCC5 genetic variants in bladder cancer development. BMC Cancer. 2011;11:101.PubMedCentralPubMedCrossRef

25.

Narter KF, Ergen A, Agaçhan B, Görmüs U, Timirci O, Isbir T. Bladder cancer and polymorphisms of DNA repair genes (XRCC1, XRCC3, XPD, XPG, APE1, hOGG1). Anticancer Res. 2009;29:1389–93.PubMed

26.

Wen H, Ding Q, Fang ZJ, Xia GW, Fang J. Population study of genetic polymorphisms and superficial bladder cancer risk in Han-Chinese smokers in Shanghai. Int Urol Nephrol. 2009;41:855–64.PubMedCrossRef

27.

García-Closas M, Malats N, Real FX, Welch R, Kogevinas M, Chatterjee N, et al. Genetic variation in the nucleotide excision repair pathway and bladder cancer risk. Cancer Epidemiol Biomarkers Prev. 2006;15:536–42.PubMedCrossRef

28.

Wu X, Gu J, Grossman HB, Amos CI, Etzel C, Huang M, et al. Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am J Hum Genet. 2006;78:464–79.PubMedCentralPubMedCrossRef

29.

Sanyal S, Festa F, Sakano S, Zhang Z, Steineck G, Norming U, et al. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis. 2004;25:729–34.PubMedCrossRef

30.

Minelli C, Thompson JR, Abrams KR, Thakkinstian A, Attia J. How should we use information about HWE in the meta-analyses of genetic association studies? Int J Epidemiol. 2008;37:136–46.PubMedCrossRef

31.

Hirschhorn JN, Lohmueller K, Byrne E. A comprehensive review of genetic association studies. Genet Med. 2002;4:45–61.PubMedCrossRef

32.

Ding D-P, He X-F, Zhang Y. Lack of association between XPG Asp1104His and XPF Arg415Gln polymorphism and breast cancer risk: a meta-analysis of case–control studies. Breast Cancer Res Treat. 2011;129:203–9.PubMedCrossRef

33.

Fagbemi AF, Orelli B, Scharer OD. Regulation of endonuclease activity in human nucleotide excision repair. DNA Repair. 2011;10:722–9.PubMedCentralPubMedCrossRef

34.

Cheng L, Sturgis EM, Eicher SA, Spitz MR, Wei Q. Expression of nucleotide excision repair genes and the risk for squamous cell carcinoma of the head and neck. Cancer. 2002;94:393–7.PubMedCrossRef

35.

Cheng L, Spitz MR, Hong WK, Wei Q. Reduced expression levels of nucleotide excision repair genes in lung cancer: a case–control analysis. Carcinogenesis. 2000;21:1527–30.PubMedCrossRef

36.

Yang Z, Nie S, Zhu H, Wu X, Jia S, Luo Y, et al. Association of p53 Arg72Pro polymorphism with bladder cancer: a meta-analysis. Gene. 2013;512:408–13.PubMedCrossRef

37.

Han SX, Wang L, Wu DQ. The association between UGT1A7 polymorphism and cancer risk: a meta-analysis. Cancer Epidemiol. 2012;36:e20120–6.CrossRef

38.

Li F, Li C, Jiang Z, Ma N, Gao X. XRCC3 T241M polymorphism and bladder cancer risk: a meta-analysis. Urology. 2011;77:511.e1-5.PubMed

Title: Quantitative assessment of the association between XPG Asp1104His polymorphism and bladder cancer risk
Authors: Chuan Liu
Qinghua Yin
Jianbing Hu
Jie Weng
Yajie Wang
Publication date: 01-02-2014
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 2/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1161-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

Association between Cyclin D1 polymorphism and oral cancer susceptibility: a meta-analysis

Rhomboid family gene expression profiling in breast normal tissue and tumor samples

Association of CYP3A4, CYP3A5 polymorphisms with lung cancer risk in Bangladeshi population

The role of Bax and Bcl-2 in gemcitabine-mediated cytotoxicity in uveal melanoma cells

Platycodin D, a triterpenoid saponin from Platycodon grandiflorum, induces G2/M arrest and apoptosis in human hepatoma HepG2 cells by modulating the PI3K/Akt pathway

COL1A1 polymorphism is associated with risks of osteosarcoma susceptibility and death

Keynote webinar | Spotlight on antibody–drug conjugates in cancer